On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after a large clinical trial showed that the medicine, approved by the Food and Drug Administration in 2022, was not effective.
Amylyx’s co-CEOs, Joshua Cohen and Justin Klee, had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit. After they made good on that promise, STAT senior writers Adam Feuerstein and Matthew Herper talked through what to make of it all.
Matt: I have to say I’m impressed. Amylyx had seemed to telegraph that it would actually follow through with withdrawing the drug when the negative data were released. But I half expected that it would still find a loophole or a way to drag things out.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.statnews.com/2024/04/04/amylyx-als-relyvirio-rare-decision/?utm_campaign=rss